Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Addit...
October 07 2019 - 3:15PM
Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical
company focused on developing and commercializing novel cancer
therapeutics that reactivate mutant tumor suppressor protein, p53,
today announced the closing of its initial public offering of
6,516,667 shares of its common stock at a price to the public of
$15.00 per share, which includes the exercise in full by the
underwriters of their option to purchase an additional 850,000
shares of common stock. Aprea Therapeutics received gross proceeds,
before deducting underwriting discounts and commissions and other
offering expenses, of approximately $97.75 million. The
shares began trading on The Nasdaq Global Select Market on October
3, 2019 under the symbol “APRE.”
J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as
joint book-running managers for the offering. The offering was made
only by means of a prospectus. A copy of the final prospectus may
be obtained from: J.P. Morgan Securities LLC, c/o J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by telephone, at (866)
803-9204; Morgan Stanley, 180 Varick Street, 2nd Floor, New York,
NY 10014, Attention: Prospectus Department or via email:
prospectus@morganstanley.com; or RBC Capital Markets, LLC,
Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York,
NY 10281, or by telephone, at (877) 822-4089.
Registration statements relating to these securities have been
filed with the U.S. Securities and Exchange Commission and became
effective under the Securities Act of 1933, as amended, on October
2, 2019. This press release does not constitute an offer to
sell or a solicitation of an offer to buy the securities described
above, nor shall there be any sale of such securities in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction.
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company
headquartered in Boston, Massachusetts with research facilities in
Stockholm, Sweden, focused on developing and commercializing novel
cancer therapeutics that reactivate mutant tumor suppressor
protein, p53. The Company’s lead product candidate is APR-246, a
small molecule in clinical development for hematologic
malignancies, including myelodysplastic syndromes (MDS) and acute
myeloid leukemia (AML).
Corporate Contacts:
Christian S. Schade
President and Chief Executive Officer
chris.schade@aprea.com
Gregory A. Korbel
Vice President of Business Development
greg.korbel@aprea.com
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jul 2023 to Jul 2024